Klin Farmakol Farm. 2023;37(2):64-67 | DOI: 10.36290/far.2023.011

Trastuzumab-induced cardiotoxicity: a review

Marek Lapka
Ústav farmakologie, 3. lékařská fakulta UK, Praha

Trastuzumab has become a highly effective treatment for HER2-positive breast and gastric cancer in combination with other chemotherapeutic agents or hormone therapy. Its clinical benefits are counterbalanced by a number of adverse effects, of which trastuzumab-induced cardiotoxicity (TZK) is a prominent one. This is a known effect of cardiac damage caused by the use of this targeted anti-cancer molecule. This article aims to discuss the mechanism, important risk factors and management of the adverse reaction. Finally, it presents options to minimize this risk and possible ways to prevent or treat it.

Keywords: trastuzumab, cardiotoxicity, adverse effect, adverse reactions, management.

Accepted: July 10, 2023; Published: July 10, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lapka M. Trastuzumab-induced cardiotoxicity: a review. Klin Farmakol Farm. 2023;37(2):64-67. doi: 10.36290/far.2023.011.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Slamon D, Eiermann W, Robert N, et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365(14):1273-1283. doi: 10.1056/NEJMoa0910383. PMID: 21991949; PMCID: PMC3268553. Go to original source... Go to PubMed...
    2. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol. 2014;32(33):3744-3752. doi: 10.1200/JCO.2014.55.5730. Epub 2014 Oct 20. PMID: 25332249; PMCID: PMC4226805. Go to original source... Go to PubMed...
    3. Lin M, Xiong W, Wang S, et al. The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment. Front Cardiovasc Med. 2022;8:821663. doi: 10.3389/fcvm.2021.821663. PMID: 35097033; PMCID: PMC8789882. Go to original source... Go to PubMed...
    4. Curigliano G, Lenihan D, Fradley M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171-190. doi: 10.1016/j.annonc.2019.10.023. PMID: 31959335; PMCID: PMC8019325. Go to original source... Go to PubMed...
    5. Leung HW, Chan AL. Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data. Expert Opin Drug Saf. 2015;14(11):1661-1671. doi: 10.1517/14740338.2015.1089231. Epub 2015 Oct 13. PMID: 26461271. Go to original source... Go to PubMed...
    6. Ezaz G, Long JB, Gross CP, et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3(1):e000472. doi: 10.1161/JAHA.113.000472. PMID: 24584736; PMCID: PMC3959671. Go to original source... Go to PubMed...
    7. Abdel-Qadir H, Thavendiranathan P, Austin PC, et al. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J. 2019;40(48):3913-3920. doi: 10.1093/eurheartj/ehz460. PMID: 31318428. Go to original source... Go to PubMed...
    8. de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol. 2014;32(20):2159-2165. doi: 10.1200/JCO.2013.53.9288. Epub 2014 Jun 9. PMID: 24912899. Go to original source... Go to PubMed...
    9. Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy. J Clin Oncol. 2017;35(8):878-884. doi: 10.1200/JCO.2015.65.7916. Epub 2016 Oct 23. PMID: 28199174. Go to original source... Go to PubMed...
    10. Ponde N, Bradbury I, Lambertini M, et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2018;168(3):631-638. doi: 10.1007/s10549-017-4628-3. Epub 2017 Dec 27. PMID: 29280043; PMCID: PMC5843537. Go to original source... Go to PubMed...
    11. Demissei BG, Hubbard RA, Zhang L, et al. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction. J Am Heart Assoc. 2020;9(2):e014708. doi: 10.1161/JAHA.119.014708. Epub 2020 Jan 21. PMID: 31959034; PMCID: PMC7033834. Go to original source... Go to PubMed...
    12. Tang GH, Acuna SA, Sevick L, et al. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting. Med Oncol. 2017;34(9):154. doi: 10.1007/s12032-017-1018-y. Epub 2017 Aug 4. PMID: 28779423. Go to original source... Go to PubMed...
    13. Vaduganathan M, Hirji SA, Qamar A, et al. Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy. JACC CardioOncol. 2019;1(1):54-65. doi: 10.1016/j.jaccao.2019.08.006. Epub 2019 Sep 24. PMID: 33083790; PMCID: PMC7571368. Go to original source... Go to PubMed...
    14. U.S. National Institutes of Health, National Library of Medicine, ClinicalTrials.gov. Preventing anthracycline cardiovascular toxicity with statins (PREVENT). https://clinicaltrials.gov/ct2/show/NCT01988571. Staženo 31.01.2023.
    15. Obasi M, Abovich A, Vo JB, et al. Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. Cancer Causes Control. 2021;32(12):1395-1405. doi: 10.1007/s10552-021-01487-1. Epub 2021 Aug 18. Erratum in: Cancer Causes Control. 2021 Sep 17;: PMID: 34406595; PMCID: PMC8541988. Go to original source... Go to PubMed...
    16. Gilchrist SC, Barac A, Ades PA, et al. American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019;139(21):e997-e1012. doi: 10.1161/CIR.0000000000000679. PMID: 30955352; PMCID: PMC7603804. Go to original source... Go to PubMed...
    17. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673-1684. doi: 10.1056/NEJMoa052122. PMID: 16236738. Go to original source... Go to PubMed...
    18. Jafari L, Akhter N. Heart failure prevention and monitoring strategies in HER2-positive breast cancer: a narrative review. Breast Cancer Res Treat. 2021;186(2):295-303. doi: 10.1007/s10549-021-06096-9. Epub 2021 Jan 22. PMID: 33481134; PMCID: PMC7820093. Go to original source... Go to PubMed...
    19. Lynce F, Barac A, Geng X, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595-603. doi: 10.1007/s10549-019-05191-2. Epub 2019 Mar 9. PMID: 30852761; PMCID: PMC6534513. Go to original source... Go to PubMed...
    20. Dempsey N, Rosenthal A, Dabas N, et al. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21-36. doi: 10.1007/s10549-021-06280-x. Epub 2021 Jun 11. PMID: 34115243. Go to original source... Go to PubMed...
    21. Min J, Wu L, Liu Y, et al. Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis. Life Sci. 2023;312:121207. doi: 10.1016/j.lfs.2022.121207. Epub 2022 Nov 17. PMID: 36403642. Go to original source... Go to PubMed...
    22. von Minckwitz G, Huang CS, Mano MS, et al. KATHERINE Investigators. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2019;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. PMID: 30516102. Go to original source... Go to PubMed...
    23. Murthy RK, Loi S, Okines A, et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020;382(7):597-609. doi: 10.1056/NEJMoa1914609. Epub 2019 Dec 11. Erratum in: N Engl J Med. 2020 Feb 6;382(6):586. PMID: 31825569. Go to original source... Go to PubMed...
    24. Huang W, Xu R, Zhou B, et al. Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy. Front Cardiovasc Med. 2022;9:912329. doi: 10.3389/fcvm.2022.912329. PMID: 35757327; PMCID: PMC9226336. Go to original source... Go to PubMed...
    25. Choksey A, Timm KN. Cancer Therapy-Induced Cardiotoxicity-A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. Int J Mol Sci. 2021;23(1):441. doi: 10.3390/ijms23010441. PMID: 35008867; PMCID: PMC8745714. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.